Antipneumococcal activity of ertapenem (MK-0826) compared to those of other agents
- PMID: 11751109
- PMCID: PMC126980
- DOI: 10.1128/AAC.46.1.42-46.2002
Antipneumococcal activity of ertapenem (MK-0826) compared to those of other agents
Abstract
The activities of ertapenem (MK-0826) and eight other agents against a range of penicillin-susceptible and -resistant pneumococci were tested by determination of MICs by the microdilution method and by the time-kill methodology. For 125 penicillin-susceptible, 74 penicillin-intermediate, and 86 penicillin-resistant pneumococci, the MICs at which 50% of isolates are inhibited (MIC(50)s) and MIC(90)s, as determined by the microdilution method, were as follows: for ertapenem, 0.016 and 0.03, 0.125 and 0.5, and 0.5 and 1.0 microg/ml for penicillin-susceptible, penicillin-intermediate, and penicillin-resistant pneumococci, respectively; for amoxicillin, < or =0.016 and 0.03, 0.25 and 1.0, and 2.0 and 2.0 microg/ml for penicillin-susceptible, penicillin-intermediate, and penicillin-resistant pneumococci, respectively; for cefprozil, 0.125 and 0.25, 1.0 and 8.0, and 16.0 and 16.0 microg/ml for penicillin-susceptible, penicillin-intermediate, and penicillin-resistant pneumococci, respectively; for cefepime, < or =0.016 and 0.06, 0.5 and 1.0, and 1.0 and 2.0 microg/ml for penicillin-susceptible, penicillin-intermediate, and penicillin-resistant pneumococci, respectively; for ceftriaxone, < or =0.016 and 0.06, 0.25 and 1.0, and 1.0 and 2.0 microg/ml for penicillin-susceptible, penicillin-intermediate, and penicillin-resistant pneumococci, respectively; for imipenem, < or =0.008 and < or =0.008, 0.03 and 0.25, and 0.25 and 0.25 microg/ml for penicillin-susceptible, penicillin-intermediate, and penicillin-resistant pneumococci, respectively; for meropenem, < or =0.008 and 0.016, 0.125 and 0.5, and 0.5 and 1.0 microg/ml for penicillin-susceptible, penicillin-intermediate, and penicillin-resistant pneumococci, respectively; and for clarithromycin, 1.0 and >32.0, 1.0 and >32.0, and >32.0 and >32.0 microg/ml for penicillin-susceptible, penicillin-intermediate, and penicillin-resistant pneumococci, respectively. For 64 strains for which quinolone MICs were increased (ciprofloxacin MICs, > or =4.0 microg/ml), the MIC(90) of ertapenem was 1.0 microg/ml and the MIC(90)s of the other beta-lactams tested and clarithromycin were >32.0 microg/ml. Against four penicillin-susceptible, four penicillin-intermediate, and four penicillin-resistant strains, testing by the time-kill methodology showed that ertapenem at two times the MIC was bacteriostatic (99% killing) after 12 h and bactericidal (99.9% killing) against all strains by 24 h, with 90% killing of all strains at two times the MIC after 6 h. At the MIC, ertapenem was bacteriostatic against all strains tested after 24 h. Although the bactericidal activity of imipenem at the MIC after 24 h was significantly greater than that of ertapenem, the kinetics of the two drugs at two times the MIC were similar after 24 h. The killing kinetics of clarithromycin were slower than those of ertapenem and other agents, with clarithromycin at two times the MIC having bactericidal activity against seven of eight macrolide-susceptible strains after 24 h.
Similar articles
-
Antipneumococcal activities of gemifloxacin compared to those of nine other agents.Antimicrob Agents Chemother. 2000 Feb;44(2):304-10. doi: 10.1128/AAC.44.2.304-310.2000. Antimicrob Agents Chemother. 2000. PMID: 10639354 Free PMC article.
-
MIC and time-kill study of antipneumococcal activities of RPR 106972 (a new oral streptogramin), RP 59500 (quinupristin-dalfopristin), pyostacine (RP 7293), penicillin G, cefotaxime, erythromycin, and clarithromycin against 10 penicillin-susceptible and -resistant pneumococci.Antimicrob Agents Chemother. 1996 Sep;40(9):2071-4. doi: 10.1128/AAC.40.9.2071. Antimicrob Agents Chemother. 1996. PMID: 8878583 Free PMC article.
-
MIC and time-kill studies of antipneumococcal activity of GV 118819X (sanfetrinem) compared with those of other agents.Antimicrob Agents Chemother. 1997 Jan;41(1):148-55. doi: 10.1128/AAC.41.1.148. Antimicrob Agents Chemother. 1997. PMID: 8980771 Free PMC article.
-
The importance of pharmacodynamic properties in treatment of penicillin resistant Streptococcus pneumoniae.Dan Med Bull. 2000 Nov;47(5):313-27. Dan Med Bull. 2000. PMID: 11155659 Review.
-
Ertapenem: a new carbapenem.Expert Opin Investig Drugs. 2001 Jun;10(6):1157-66. doi: 10.1517/13543784.10.6.1157. Expert Opin Investig Drugs. 2001. PMID: 11772242 Review.
Cited by
-
Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin.Antimicrob Agents Chemother. 2005 May;49(5):1932-42. doi: 10.1128/AAC.49.5.1932-1942.2005. Antimicrob Agents Chemother. 2005. PMID: 15855516 Free PMC article.
-
Activities of ertapenem, a new long-acting carbapenem, against penicillin-sensitive or -resistant pneumococci in experimental meningitis.Antimicrob Agents Chemother. 2003 Jun;47(6):1943-7. doi: 10.1128/AAC.47.6.1943-1947.2003. Antimicrob Agents Chemother. 2003. PMID: 12760871 Free PMC article.
-
Ertapenem: a review of its use in the management of bacterial infections.Drugs. 2003;63(17):1855-78. doi: 10.2165/00003495-200363170-00006. Drugs. 2003. PMID: 12921489 Review.
-
Ertapenem: a review of its use in the treatment of bacterial infections.Drugs. 2005;65(15):2151-78. doi: 10.2165/00003495-200565150-00013. Drugs. 2005. PMID: 16225376 Review.
-
Meropenem: a review of its use in the treatment of serious bacterial infections.Drugs. 2008;68(6):803-38. doi: 10.2165/00003495-200868060-00006. Drugs. 2008. PMID: 18416587 Review.
References
-
- Appelbaum, P. C. 1992. Antimicrobial resistance in Streptococcus pneumoniae—an overview. Clin. Infect. Dis. 15:77–83. - PubMed
-
- Block, S., C. J. Harrison, J. A. Hedrick, R. D. Tyler, R. A. Smith, E. Keegan, and S. A. Chartrand. 1995. Penicillin-resistant Streptococcus pneumoniae in acute otitis media: risk factors, susceptibility patterns and antimicrobial management. Pediatr. Infect. Dis. J. 14:751–759. - PubMed
-
- Chen, D. K., A. McGeer, J. C. de Azavedo, and D. E. Low. 1999. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N. Engl. J. Med. 341:233–239. - PubMed
-
- Friedland, I. R., and G. S. Istre. 1992. Management of penicillin-resistant pneumococcal infections. Pediatr. Infect. Dis. J. 11:433–435. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources